Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxart Inc (NQ: VXRT )

0.7699 +0.0046 (+0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Recap: Vaxart Q4 Earnings
Vaxart (NASDAQ:VXRT) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Vaxart... 
Via Benzinga
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart
Macy's Inc (NYSE:M) retail stores have something for everyo... 
Via Benzinga
Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger
VXRT stock is more than a Covid-19 meme trade. But is there enough fundamentals there to support an investment heading into 2022? 
Via InvestorPlace
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine
As the Covid-19 vaccine maker expands into a second manufacturing facility, VXRT stock remains an undervalued gem. 
Via InvestorPlace
Vaxart Stock Crosses 2 Key Levels Friday: What's Next?
Vaxart Inc. (NASDAQ:VXRT) shares were trading higher ... 
Via Benzinga
Vaxart Stock Breaks Out Of Pennant Pattern: Now What?
Vaxart Inc. (NASDAQ:VXRT) shares were trading higher ... 
Via Benzinga
Why Vaxart Stock Is About Ready To See A Breakout
Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Wednes... 
Via Benzinga
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Vaccine Against Omicron
Vaxart Inc (NASDAQ: VXRT) plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the omicron SARS-CoV-2 variant in two different... 
Via Benzinga
VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down
Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart. 
Via InvestorPlace
Cramer Gives His Opinion On Nokia, Delta Air Lines And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said DigitalOcean Holdings, Inc. (NYSE: 
Via Benzinga
Vaxart Stock Is Being Squeezed At The End Of A Pattern
Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Thursd... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021
Upgrades UBS upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
Don’t Write Off Vaxart, As Its Oral Vaccine Still Has a Chance
Vaxart stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative. 
Via InvestorPlace
Exposures COVID-19
Can This COVID Vaccine Stock Help Make You Rich?
This biotech has a nifty trick potentially up its sleeve. 
Via The Motley Fool
Exposures COVID-19
Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up
Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesd... 
Via Benzinga
NASDAQ:VLDR Shareholder Notice: Update in Lawsuit Against Velodyne Lidar, Inc.
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Velodyne Lidar, Inc. (NASDAQ:VLDR). 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:VXRT Investor Alert: Update in Lawsuit Against Vaxart, Inc.
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Vaxart, Inc. (NASDAQ:VXRT). 
Via SBWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late?
The company is working on a vaccine candidate that doesn't involve a needle. 
Via The Motley Fool
Why Vaxart Shares Are Trading Higher Today
Vaxart Inc (NASDAQ: VXRT) is trading higher Friday after the company reported a Duke University-led study published in bioRxiv showed that the company's investigational... 
Via Benzinga
18 Stocks Moving in Friday's Pre-Market Session
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine... 
Via Benzinga
Why Vaxart Shares Are Surging In Thursday's After-Hours Session
Vaxart Inc (NASDAQ: VXRT) is surging higher in after-hours trading Thursday after the company reported a Duke University-led study published in bioRxiv showed that the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Vaxart (NASDAQ:VXRT) shares incr... 
Via Benzinga
Why Vaxart Stock Tumbled in September
A COVID-19 antiviral pill may undermine the biotech's value proposition. 
Via The Motley Fool
Exposures COVID-19
Vaxart Starts Recruitment In Mid-Stage COVID-19 Oral Vaccine Trial
Vaxart Inc (NASDAQ: VXRT) has begun recruiting subjects for its Phase 2 COVID-19 oral tablet vaccine clinical trial. Related: FDA Clears Vaxart's... 
Via Benzinga
Exposures COVID-19 Product Safety
Why Investing in VXRT Stock is a Coin Flip
Vaxart is a gamble for biotechnology investors, with its upside too dependent on the approval of an oral vaccine. 
Via InvestorPlace
Exposures COVID-19
What's Going On With Vaxart's Stock?
Vaxart Inc. (NASDAQ: VXRT) shares traded higher Tuesday after a study titled "A Phase 2 Trial With an Oral Tableted Covid-19 Vaccine" was posted to Clinicaltrials.gov.... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. 
Via InvestorPlace
Exposures COVID-19
Vaxart Traders Should Not Dismiss the Vaccine Maker’s Momentum
The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19. 
Via InvestorPlace
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.